Company Profile

TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.

Employees

Sector

Biotechnology & Medical Research

More about the company

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	+67.53%

01/10/18	TxCell : Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares	PR
23/07/18	TxCell : Sangamo Therapeutics to Acquire TxCell	PR
10/07/18	TxCell : exercises in-license option to the University of British Columbia’s intellectual property rights of the HLA-A2 CAR-Treg program	PU
21/06/18	TxCell : First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018	PU
28/05/18	TxCell : to present its latest manufacturing process achievements at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress	PU

03/12/18	TxCell : acquisition par Sangamo finalisée
27/11/18	TxCell : retrait obligatoire ce jeudi
26/11/18	TxCell : près de sept millions d'actions apportées à l'OPAS
23/11/18	TXCell : Sangamo Therapeutics dépasse les 90%
15/11/18	TxCell : 'la rencontre avec Sangamo était une évidence'

Manager	Title	Age	Since
Sandrine Boulet COO	Chief Operating Officer	50	-
Pierre Desreumaux PRN	Corporate Officer/Principal	-	-
Bernard Malissen PRN	Corporate Officer/Principal	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TXCELL	-.--%	-.--%	-	-	0
ARGENX SE	-0.10%	+0.10%	+74.33%	+133.26%	57.73B
WUXI APPTEC CO., LTD.	-3.80%	-6.24%	+67.04%	+86.36%	54.69B
BIONTECH SE	+0.12%	+0.67%	-14.88%	-12.34%	23.75B
INSMED INCORPORATED	+1.46%	+5.92%	+16.48%	+468.63%	24.18B
WUXI BIOLOGICS (CAYMAN) INC.	-2.70%	+4.25%	+40.38%	-3.72%	19.82B
GENMAB A/S	+3.78%	+5.65%	+44.99%	-26.23%	17.14B
PHARMAESSENTIA CORPORATION	+3.46%	+17.72%	+206.66%	+364.07%	16.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.81%	+18.00%	+41.99%	-	15.57B
EXELIXIS, INC.	+3.06%	+5.17%	+29.59%	+196.35%	13.96B
Average	+0.34%	+5.56%	+56.29%	+150.80%	27.06B
Weighted average by Cap.	-0.38%	+3.34%	+57.90%	+139.33%

TxCell Stock

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Press Releases: TxCell

News in other languages: TxCell

Managers and Directors: TxCell

Bio Therapeutic Drugs

Company Profile